Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis (Cochrane Review)

A substantive amendment to this systematic review was last made on 24 January 2000. Cochrane reviews are regularly checked and updated if necessary.

Background: Leukotriene receptor antagonists are a new class of drug that were initially identified for use in asthma. As they have an effect on neutrophil mediated inflammation, they may be of benefit in bronchiectasis.

Objectives: To determine whether leukotriene receptor antagonists have any additive benefit over and above conventional treatment for bronchiectasis (usually consisting of antibiotics and postural drainage).

Search strategy: The Cochrane Airways Group clinical trials register derived from MEDLINE, EMBASE and hand searching of major journals was searched using the terms:Bronchiec* AND leukotrien* OR anti-leuk* OR cysteinyl, Bronchiec* AND monteluk*, Bronchiec* AND zafirluk*

Selection criteria: Only randomised, controlled trials were considered

Data collection and analysis: The results of searches were analysed by both authors

Main results: No randomised, controlled trials were identified. An update search conducted in February 2002 did not yield any further studies.

Reviewers' conclusions: Further research is required to establish any benefit from the use of leukotriene antagonists in bronchiectasis.

Citation: Corless JA, Warburton CJ. Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis (Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Oxford: Update Software.

---

This is an abstract of a regularly updated, systematic review prepared and maintained by the Cochrane Collaboration. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).

The Cochrane Library is designed and produced by Update Software Ltd.

Update Software Ltd, Summertown Pavilion, Middle Way, Oxford OX2 7LG, UK
(Tel:+44 1865 513902; Fax:+44 1865 516918)

File Reference: AB002174.htm